Edwards Lifesciences Analyst Ratings
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75
Edwards Lifesciences Analyst Ratings
Buy Rating Affirmed for Edwards Lifesciences on Growth and Market Positioning Prospects
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Edwards Lifesciences Analyst Ratings
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98
Robust Growth and R&D Focus Solidify Buy Rating for Edwards Lifesciences
Edwards Lifesciences Analyst Ratings
Edwards Lifesciences: A Buy Rating With Strong Growth Prospects and Positive Market Dynamics
Edwards Lifesciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
Hold Rating Justified for Edwards Lifesciences Amid TAVR Segment Uncertainties
Maintaining Buy Rating on Edwards Lifesciences Amid Mixed TAVR Performance and Strong TMTT Growth
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)
Bernstein Adjusts Price Target on Edwards Lifesciences to $73 From $72
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
Edwards Lifesciences Analyst Ratings
Canaccord Genuity Trims Price Target on Edwards Lifesciences to $85 From $86